

# Contents

### Highlights of This Issue 953

### SPECIAL FEATURES

#### CCR Translations

- 955 **Reading the Tea Leaves of Tumor-Mediated Immunosuppression**  
Rimas J. Orentas  
*See article, p. 1116*
- 958 **Can the "Right" EGFR-Specific mAb Dramatically Improve EGFR-Targeted Therapy?**  
Francesco Sabbatino and Soldano Ferrone  
*See article, p. 1126*

#### CCR New Strategies

- 961 **New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential**  
Susana Banerjee and Stanley B. Kaye

#### Statistics in Clinical Cancer Research

- 969 **Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials**  
Roger Sidhu, Alan Rong, and Steve Dahlberg

#### Molecular Pathways

- 977 **Molecular Pathways: Targeting PARP in Cancer Treatment**  
Khanh Do and Alice P. Chen

#### Review

- 985 **Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease**  
Amit Agarwal and Irene M. Ghobrial

#### CCR Focus

- 996 **Waking the Immune System at Last**  
Susan E. Bates

- 997 **Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination**  
Ignacio Melero, Antonio M. Grimaldi, Jose L. Perez-Gracia, and Paolo A. Ascierto
- 1009 **Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types**  
Paolo A. Ascierto, Michael Kalos, David A. Schaer, Margaret K. Callahan, and Jedd D. Wolchok
- 1021 **Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer**  
Mario Sznol and Lieping Chen
- 1035 **Agonistic CD40 Antibodies and Cancer Therapy**  
Robert H. Vonderheide and Martin J. Glennie
- 1044 **Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells**  
Ignacio Melero, Daniel Hirschhorn-Cymerman, Aizea Morales-Kastresana, Miguel F. Sanmamed, and Jedd D. Wolchok
- 1054 **Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors**  
Eli Gilboa, James McNamara II, and Fernando Pastor

#### HUMAN CANCER BIOLOGY

- 1063 **Modeling Boundary Conditions for Balanced Proliferation in Metastatic Latency**  
Donald P. Taylor, Jakob Z. Wells, Andrej Savol, Chakra Chennubhotla, and Alan Wells
- 1071 **ZEB1 Promotes Invasiveness of Colorectal Carcinoma Cells through the Opposing Regulation of uPA and PAI-1**  
Ester Sánchez-Tilló, Oriol de Barrios, Laura Siles, Pier G. Amendola, Douglas S. Darling, Miriam Cuatrecasas, Antoni Castells, and Antonio Postigo

1083 **Downregulation of miR-138 Sustains NF- $\kappa$ B Activation and Promotes Lipid Raft Formation in Esophageal Squamous Cell Carcinoma**

Hui Gong, Libing Song, Chuyong Lin, Aibin Liu, Xi Lin, Jueheng Wu, Mengfeng Li, and Jun Li

1094 **Lack of Estrogen Receptor- $\alpha$  Is Associated with Epithelial-Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma**

Elisabeth Wik, Maria B. Ræder, Camilla Krakstad, Jone Trovik, Even Birkeland, Erling A. Hoivik, Siv Mjos, Henrica M.J. Werner, Monica Mannelqvist, Ingunn M. Stefansson, Anne M. Oyan, Karl H. Kalland, Lars A. Akslen, and Helga B. Salvesen

## CANCER THERAPY: PRECLINICAL

1106 **PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas**

Katherine Walsh, Matthew S. McKinney, Cassandra Love, Qingquan Liu, Alice Fan, Ameer Patel, Jason Smith, Anne Beaven, Dereje D. Jima, and Sandeep S. Dave

1116 **Polyphenol E Enhances the Antitumor Immune Response in Neuroblastoma by Inactivating Myeloid Suppressor Cells**

Giorgia Santilli, Izabela Piotrowska, Sandra Cantilena, Olesya Chayka, Marco D'Alicarnasso, Daniel A. Morgenstern, Nourredine Himoudi, Katie Pearson, John Anderson, Adrian J. Thrasher, and Arturo Sala

*See commentary, p. 955*

1126 **GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior *In Vivo* Efficacy Compared with Cetuximab**

Christian A. Gerdes, Valeria Gonzalez Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine Lang, Michaela Roemmele, Ekkehard Moessner, Olivier Freytag, Thomas Friess, Carola H. Ries, Birgit Bossenmaier, Hans Joachim Mueller, and Pablo Umaña

*See commentary, p. 958*

1139 **Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice**

Hirohiko Kamiyama, Sherri Rauenzahn, Joong Sup Shim, Collins A. Karikari, Georg Feldmann, Li Hua, Mihoko Kamiyama, F. William Schuler, Ming-Tseh Lin, Robert M. Beaty, Balasubramanyam Karanam, Hong Liang, Michael E. Mullendore, Guanglan Mo, Manuel Hidalgo, Elizabeth Jaffee, Ralph H. Hruban, H.A. Jinnah, Richard B.S. Roden, Antonio Jimeno, Jun O. Liu, Anirban Maitra, and James R. Eshleman

1147 **Measles Virus Vaccine-Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells**

Jean-Baptiste Guillerme, Nicolas Boisgerault, David Roulois, Jérémie Ménager, Chantal Combredet, Frédéric Tangy, Jean-François Fonteneau, and Marc Gregoire

1159 **Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells**

Susan E. Pratt, Sara Durland-Busbice, Robert L. Shepard, Kathleen Heinz-Taheny, Philip W. Iversen, and Anne H. Dantzig

1169 **Inactivation or Loss of TTP Promotes Invasion in Head and Neck Cancer via Transcript Stabilization and Secretion of MMP9, MMP2, and IL-6**

Elizabeth A. Van Tubergen, Rajat Banerjee, Min Liu, Robert Vander Broek, Emily Light, Shiuhyang Kuo, Stephen E. Feinberg, Amanda L. Willis, Gregory Wolf, Thomas Carey, Carol Bradford, Mark Prince, Francis P. Worden, Keith L. Kirkwood, and Nisha J. D'Silva

1180 **mTORC1 Inhibitors Suppress Meningioma Growth in Mouse Models**

Doreen Pachow, Nadine Andrae, Nadine Kliese, Frank Angenstein, Oliver Stork, Annette Wilisch-Neumann, Elmar Kirches, and Christian Mawrin

## IMAGING, DIAGNOSIS, PROGNOSIS

1190 **Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics**

Antoine Italiano, Pauline Lagarde, Céline Brulard, Philippe Terrier, Marick Laë, Bernard Marques, Dominique Ranchere-Vince, Jean-Jacques Michels, Martine Trassard, Angela Cioffi, Sophie Piperno-Neumann, Christine Chevreau, Jean-Yves Blay, Corinne Delcambre, Nicolas Isambert, Nicolas Penel, Jacques-Olivier Bay, Sylvie Bonvalot, Axel Le Cesne, Jean-Michel Coindre, and Frédéric Chibon

1197 **A 13-Gene Signature Prognostic of HPV-Negative OSCC: Discovery and External Validation**

Pawadee Lohavanichbutr, Eduardo Méndez, F. Christopher Holsinger, Tessa C. Rue, Yuzheng Zhang, John Houck, Melissa P. Upton, Neal Futran, Stephen M. Schwartz, Pei Wang, and Chu Chen

1204 **Association of RASSF1A and p63 with Poor Recurrence-Free Survival in Node-Negative Stage I–II Non-Small Cell Lung Cancer**  
Eunkyung Ko, Bo Bin Lee, Yujin Kim, Eun Ju Lee, Eun Yoon Cho, Jungho Han, Young Mog Shim, Joobae Park, and Duk-Hwan Kim

1213 **Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer**  
Swati Suryawanshi, Anda M. Vlad, Hui-Min Lin, Gina Mantia-Smaldone, Robin Laskey, MinJae Lee, Yan Lin, Nicole Donnellan, Marcia Klein-Patel, Ted Lee, Suketu Mansuria, Esther Elishaev, Raluca Budiu, Robert P. Edwards, and Xin Huang

## CANCER THERAPY: CLINICAL

1225 **BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma**  
Dennie T. Frederick, Adriano Piris, Alexandria P. Cogdill, Zachary A. Cooper, Cecilia Lezcano, Cristina R. Ferrone, Devarati Mitra, Andrea Boni, Lindsay P. Newton, Chengwen Liu, Weiyi Peng, Ryan J. Sullivan, Donald P. Lawrence, F. Stephen Hodi, Willem W. Overwijk, Gregory Lizée, George F. Murphy, Patrick Hwu, Keith T. Flaherty, David E. Fisher, and Jennifer A. Wargo

1232 **Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer**  
Colin D. Weekes, Daniel D. Von Hoff, Alex A. Adjei, Diane P. Leffingwell, S. Gail Eckhardt, Lia Gore, Karl D. Lewis, Glen J. Weiss, Ramesh K. Ramanathan, Grace K. Dy, Wen W. Ma, Beth Sheedy, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li-Tain Yeh, Ronald L. Dubowy, Michael Jeffers, Prabhu Rajagopalan, and Neil J. Clendeninn

1244 **Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies**  
Dong M. Shin, Hongzheng Zhang, Nabil F. Saba, Amy Y. Chen, Sreenivas Nannapaneni, A.R.M. Ruhul Amin, Susan Müller, Melinda Lewis, Gabriel Sica, Scott Kono, Johann C. Brandes,

William J. Grist, Rachel Moreno-Williams, Jonathan J. Beitler, Sufi M. Thomas, Zhengjia Chen, Hyung Ju C. Shin, Jennifer R. Grandis, Fadlo R. Khuri, and Zhuo Georgia Chen

1257 **Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma**  
Eric Angevin, Jose A. Lopez-Martin, Chia-Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Daniel Castellano, Jean-Charles Soria, Paramita Sen, Julie Chang, Michael Shi, Andrea Kay, and Bernard Escudier

1269 **A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol**  
Jia Ji, Diane R. Mould, Kristie A. Blum, Amy S. Ruppert, Ming Poi, Yuan Zhao, Amy J. Johnson, John C. Byrd, Michael R. Grever, and Mitch A. Phelps

## PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

1281 **Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial**  
Bryan P. Schneider, Robert J. Gray, Milan Radovich, Fei Shen, Gail Vance, Lang Li, Guanglong Jiang, Kathy D. Miller, Julie R. Gralow, Maura N. Dickler, Melody A. Cobleigh, Edith A. Perez, Tamara N. Shenkier, Kirsten Vang Nielsen, Sven Müller, Ann Thor, George W. Sledge Jr, Joseph A. Sparano, Nancy E. Davidson, and Sunil S. Badve

1290 **Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF**  
Christopher T. Campbell, James L. Gulley, Oyindasola Oyelaran, James W. Hodge, Jeffrey Schlom, and Jeffrey C. Gildersleeve

## LETTERS TO THE EDITOR

1300 **Colon Cancer Mutation: Prognosis/Prediction—Letter**  
Aziz Zaanani, Franck Bonnetain, Franck A. Sinicrope, Pierre Laurent-Puig, and Julien Taïeb

1301 **Colon Cancer Mutation: Prognosis/Prediction—Response**  
Patrick G. Gavin, Soonmyung Paik, Greg Yothers, and Kay L. Pogue-Geile

---

1302 **Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Letter**  
Brian J. Tunquist, Kenneth W. Wood, and Duncan H. Walker

1303 **Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Letter**  
Michel D. Wissing, Michael A. Carducci, Hans Gelderblom, and Paul J. van Diest

1304 **Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Response**  
Edina Komlodi-Pasztor, Dan L. Sackett, and Tito Fojo


### CORRECTION

1305 **Correction: Therapeutic Targeting of PELP1 Prevents Ovarian Cancer Growth and Metastasis**

---

### ABOUT THE COVER

The anticancer activity of green tea catechins has been known for a long time, but the mechanism of action is still unclear. The cover figure shows terminal differentiation of cancer-induced myeloid cells in the presence of the green tea catechin formulation Polyphenon E. The differentiation of immunosuppressive myeloid cells by green tea catechins promotes an antitumor T-cell response in neuroblastoma. For details, see the article by Santilli and colleagues on page 1116 of this issue.



# Clinical Cancer Research

**19 (5)**

*Clin Cancer Res* 2013;19:953-1305.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/19/5>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/19/5>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.